Dongwha Pharm.Co (000020) Fundamentals 2026 — P/E 7.3x, Revenue Analysis | SniperIQ
Dongwha Pharm.Co (000020) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩136.1B, trading at ₩4910.00 on the KSC. This SniperIQ fundamentals page covers Dongwha Pharm.Co's valuation (P/E 7.3x, P/B 0.4x), profitability (net margin 3.7%), revenue (₩496.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Dongwha Pharm.Co's market cap?
Dongwha Pharm.Co (000020) has a market capitalization of approximately ₩136.1B, trading at ₩4910.00 on the KSC. Market cap moves with the live share price.
What is Dongwha Pharm.Co's P/E ratio?
Dongwha Pharm.Co's trailing twelve-month P/E ratio is 7.3x, with a price-to-book (P/B) of 0.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Dongwha Pharm.Co?
Dongwha Pharm.Co runs a net profit margin of 3.7%, a gross margin of 43.0%, and an operating margin of 1.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Dongwha Pharm.Co generate?
Dongwha Pharm.Co reported revenue of ₩496.4B for fiscal year 2025, with net income of ₩8.7B and earnings per share (EPS) of 313.37. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Dongwha Pharm.Co pay a dividend?
Dongwha Pharm.Co offers a trailing dividend yield of about 5.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Dongwha Pharm.Co financially healthy?
Dongwha Pharm.Co carries a debt-to-equity ratio of 0.32x and a current ratio of 1.16x, with a market beta of 0.36. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Dongwha Pharm.Co a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Dongwha Pharm.Co (000020) the key facts are: market cap ₩136.1B, P/E 7.3x, revenue ₩496.4B, 52-week range 4695-7560. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Dongwha Pharm.Co's full fundamentals live
Get Dongwha Pharm.Co's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.